Phase II Trial of Ipilimumab ± Talimogene Laherparepvec in Unresected Stage IIIB-IV Melanoma

June 2-6, 2017; Chicago, Illinois
Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 228 KB
Released: June 6, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the impact of new data on treatment algorithms in melanoma.

Jeffrey S. Weber, MD, PhD
Program Director
person default Allison Betof Warner, MD, PhD Hussein Tawbi, MD, PhD
Released: September 10, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the changing therapeutic landscape in advanced melanoma.

person default Allison Betof Warner, MD, PhD Hussein Tawbi, MD, PhD Jeffrey S. Weber, MD, PhD Released: September 7, 2021

Download this short slideset from Clinical Care Options (CCO) on managed care and specialty pharmacy considerations with CAR T-cell therapy

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue